- Home
- AVR vs PCK Comparison
AVR vs PCK Comparison
Compare AVR & PCK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVR
- PCK
- Stock Information
- Founded
- AVR 1999
- PCK 2002
- Country
- AVR Australia
- PCK United States
- Employees
- AVR N/A
- PCK N/A
- Industry
- AVR
- PCK Trusts Except Educational Religious and Charitable
- Sector
- AVR
- PCK Finance
- Exchange
- AVR NYSE
- PCK Nasdaq
- Market Cap
- AVR 215.6M
- PCK 183.5M
- IPO Year
- AVR 2024
- PCK N/A
- Fundamental
- Price
- AVR $6.18
- PCK $5.81
- Analyst Decision
- AVR Strong Buy
- PCK
- Analyst Count
- AVR 4
- PCK 0
- Target Price
- AVR $16.50
- PCK N/A
- AVG Volume (30 Days)
- AVR 156.0K
- PCK 79.7K
- Earning Date
- AVR 01-01-0001
- PCK 01-01-0001
- Dividend Yield
- AVR N/A
- PCK 4.58%
- EPS Growth
- AVR N/A
- PCK N/A
- EPS
- AVR N/A
- PCK N/A
- Revenue
- AVR $2,826,588.00
- PCK N/A
- Revenue This Year
- AVR N/A
- PCK N/A
- Revenue Next Year
- AVR N/A
- PCK N/A
- P/E Ratio
- AVR N/A
- PCK N/A
- Revenue Growth
- AVR N/A
- PCK N/A
- 52 Week Low
- AVR $5.10
- PCK $4.85
- 52 Week High
- AVR $6.29
- PCK $6.33
- Technical
- Relative Strength Index (RSI)
- AVR N/A
- PCK 60.65
- Support Level
- AVR N/A
- PCK $5.71
- Resistance Level
- AVR N/A
- PCK $5.71
- Average True Range (ATR)
- AVR 0.00
- PCK 0.05
- MACD
- AVR 0.00
- PCK 0.02
- Stochastic Oscillator
- AVR 0.00
- PCK 96.15
About AVR ANTERIS TECHNOLOGIES GLOBAL CORP
Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. Its product, the DurAVR THV system, represents a product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Its DurAVR THV system consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold.
About PCK Pimco California Municipal Income Fund II of Beneficial Interest
PIMCO CA Muni Income Fund II is a closed-ended investment company. Its investment objective is to seek to provide current income exempt from federal and California income tax. The company portfolio of investment comprises of different sector investments such as healthcare, education, property, and others.